Publications by authors named "Pontus Jureen"

Claim this Profile
A
An outbreak investigation of non- Legionnaires' disease in Sweden, April to August 2018: Gardening and use of commercial bagged soil associated with infections.
Emma Löf, Fanny Chereau, Pontus Jureen, Sabina Andersson, Kristina Rizzardi

Euro Surveill· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex.
Matthias Merker, Thomas A Kohl, Ivan Barilar, Sönke Andres, Philip W Fowler, Pontus Jureen

Genome Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network Experiences from a Cross-Sector Biosafety Level-3 Laboratory Collaboration: A Swedish Forum for Biopreparedness Diagnostics.
Johanna Thelaus, Anna Lindberg, Susanne Thisted Lambertz, Mona Byström, Mats Forsman, Pontus Jureen

Health Secur· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prioritization of High Consequence Viruses to Improve European Laboratory Preparedness for Cross-Border Health Threats.
Carla Nisii, Roland Grunow, Andreas Brave, Giuseppe Ippolito, Daniela Jacob, Pontus Jureen

Adv Exp Med Biol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.
Abigail L Manson, Keira A Cohen, Thomas Abeel, Christopher A Desjardins, Derek T Armstrong, Pontus Jureen

Nat Genet· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Drug-Resistant Mycobacterium tuberculosis.
Anna Engström, Pontus Juréen

Methods Mol Biol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
Katarina Niward, Kristian Ängeby, Erja Chryssanthou, Jakob Paues, Judith Bruchfeld, Pontus Jureen

J Antimicrob Chemother· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A luciferase-based assay for rapid assessment of drug activity against Mycobacterium tuberculosis including monitoring of macrophage viability.
Marie C Larsson, Maria Lerm, Kristian Ängeby, Michaela Nordvall, Pontus Juréen

J Microbiol Methods· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of heteroresistant Mycobacterium tuberculosis by pyrosequencing.
Anna Engström, Sven Hoffner, Pontus Juréen

J Clin Microbiol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidrug-resistant Myobacterium tuberculosis caused by the Beijing genotype and a specific T1 genotype clone (SIT No. 266) is widely transmitted in Minsk.
Aksana Zalutskaya, Maria Wijkander, Pontus Jureen, Alena Skrahina, Sven Hoffner

Int J Mycobacteriol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis.
Kristian Ängeby, Pontus Juréen, Erja Chryssanthou, Thomas Schön

Int J Mycobacteriol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions.
Senia Rosales-Klintz, Pontus Jureen, Aksana Zalutskayae, Alena Skrahina, Biao Xu

Int J Mycobacteriol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.
Kristian Ängeby, Pontus Juréen, Gunnar Kahlmeter, Sven E Hoffner, Thomas Schön

Bull World Health Organ· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing.
Anna Engström, Nora Morcillo, Belen Imperiale, Sven E Hoffner, Pontus Juréen

J Clin Microbiol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.
Kristian Angeby, Christian G Giske, Pontus Juréen, Thomas Schön, Jotam G Pasipanodya

Antimicrob Agents Chemother· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
Anna Engström, Nasrin Perskvist, Jim Werngren, Sven E Hoffner, Pontus Juréen

J Antimicrob Chemother· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis.
Anandi Martin, Fabienne Paasch, Sven Docx, Krista Fissette, Belen Imperiale

J Antimicrob Chemother· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rifampin-isoniazid oligonucleotide typing: an alternative format for rapid detection of multidrug-resistant Mycobacterium tuberculosis.
Iván Hernández-Neuta, Andrés Varela, Anandi Martin, Andrea von Groll, Pontus Jureen

J Clin Microbiol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
Thomas Schön, Pontus Juréen, Christian G Giske, Erja Chryssanthou, Erik Sturegård

J Antimicrob Chemother· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
Andrea Von Groll, Anandi Martin, Pontus Jureen, Sven Hoffner, Peter Vandamme

Antimicrob Agents Chemother· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.
Pontus Juréen, Jim Werngren, Juan-Carlos Toro, Sven Hoffner

Antimicrob Agents Chemother· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants.
Emma Huitric, Jim Werngren, Pontus Juréen, Sven Hoffner

Antimicrob Agents Chemother· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology.
Pontus Jureen, Lars Engstrand, Solveig Eriksson, Anders Alderborn, Margareta Krabbe

J Clin Microbiol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis.
Pontus Juréen, Jim Werngren, Sven E Hoffner

Tuberculosis (Edinb)· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.
Annika Krüüner, Pontus Jureen, Klavdia Levina, Solomon Ghebremichael, Sven Hoffner

Antimicrob Agents Chemother· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis